Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Abbott GmbH & Co. KG
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral experienced, HIV-1 Infected Subjects
The primary objectives of this study are to compare the safety, tolerability and antiviral activity of QD and BID dosing of the lopinavir/ritonavir tablet formulation in subjects with detectable viral...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
To determine the efficacy of 0.10 mg/kg and 0.25 mg/kg ABT-869 using Response Evaluation Criteria in Solid Tumors (RECIST) criteria and to establish the safety/tolerability profile of ABT-869 in subje...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Study Comparing the Safety and Analgesic Efficacy of ABT-110 in Subjects with Pain from Osteoarthritis of the Knee
The primary objective of this study is to compare the safety, tolerability and analgesic efficacy of ABT-110 administered SC once every 8 weeks (q8w) for a total of 3 doses to placebo in subjects with...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A multi-center, randomized, double-blind, placebo-controlled study on the Human Anti-TNF monoclonal antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects with Crohn s Disease Involving the Colon
To demonstrate the efficacy of adalimumab on mucosal healing in subjects with moderate to severe ileocolonic Crohn s disease.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary Hyperparathyroidism
To evaluate the superiority of paricalcitol as compared to cinacalcet with supplemental low dose vitamin D therapy, as assessed by the proportion of haemodialysis subjects that achieve a mean iPTH val...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 years with Moderate to Severe Chronic Kidney Disease. Estudio en fase 3 prospectivo, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la farmacocinética, la seguridad y la eficacia de paricalcitol cápsulas en cuanto a la reducción de la concentración sérica de hormona paratiroidea intacta en niños y adolescentes de entre 10 y 16 años con nefropatía crónica moderada o grave
Los objetivos del estudio son los siguientes: Farmacocinética de una dosis única (parte I) Determinar la seguridad, la tolerabilidad y la farmacocinética de una dosis única de 3 μg de paricalcito...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Study Comparing the Safety and Analgesic Efficacy of ABT-110 in Subjects with Chronic Low Back Pain Sperimentazione per confrontare la sicurezza e l'efficacia analgesica di ABT-110 in soggetti con dolore lombare cronico
The primary objective for this study is to compare the safety, tolerability and the analgesic efficacy of ABT-110 administered subcutaneously (SC) once every 8 weeks (q8w) for a total of two doses t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 3, Multicenter, Randomized, Double-Blind,Double-Dummy, Placebo-Controlled StudyComparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects withModerate to Severe Chronic Plaque Psoriasis
To compare the safety, tolerability and clinical efficacy of adalimumab with placebo and with methotrexate in the treatment of moderate to severe chronic plaque psoriasis over a 16-week period.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic Breast Cancer
To assess if the addition of oral ABT-869 to paclitaxel can prolong progression-free survival (PFS) compared to paclitaxel alone in the first line treatment of subjects with metastatic breast cancer.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
To assess if the addition of oral ABT-751 at the recommended phase 2 dose (RPTD) of 200mg QD to standard docetaxal can prolong progression free survival (PFS) compared to docetaxal alone in subjects w...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
Suivant